Biological therapies in nonsmall cell lung cancer
نویسندگان
چکیده
منابع مشابه
Combination of biological therapies in non-small cell lung cancer.
Growth factor receptors control critical functions for human cancer cells, such as growth, angiogenesis, metastatic spread, inhibition of cell death and apoptosis via sequential signalling activation of several kinases involved in transduction pathways. Among those receptors, the epidermal growth factor receptor (EGFR) and its ligands EGF and TGFa have been extensively investigated for their cr...
متن کاملSecond-line combination therapies in nonsmall cell lung cancer without known driver mutations.
In advanced nonsmall cell lung cancer (NSCLC) patients, platinum-based combination chemotherapy is standard treatment in the first-line setting; however, the large majority of patients ultimately progress. For more than a decade, single-agent therapy with docetaxel, pemetrexed or erlotinib has been the standard of care after failure with platinum salts, showing some benefit over best supportive...
متن کاملTargeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
Nonsmall cell lung cancer (NSCLC) is diagnosed in the majority of patients in advanced stage of disease. In this setting, the prognosis is very poor with median survival of 9– 12 months and palliative chemotherapy being the standard of care. However, chemotherapy in advanced disease seems to have reached a plateau with no doublet combination shown to be clinically superior to the others. Advanc...
متن کاملSurgery for nonsmall cell lung cancer.
Surgery remains the best curative option in patients with early stage lung cancer (stage I and II). Developments in minimally invasive techniques now allow surgeons to perform lung resections on elderly patients, patients with poor pulmonary function or significant cardiopulmonary comorbidities. New techniques, such as stereotactic radiotherapy and ablative procedures, are being evaluated in ea...
متن کاملThyroid Metastasis from Nonsmall Cell Lung Cancer
Background. Thyroid metastases are rare. Clinically, they represent less than 4% of thyroid malignancy in clinical studies. Aim. To assess various presentations and therapy for patients with lung cancer metastatic in the thyroid. Materials and Methods. We report a case of metastatic adenocarcinoma of the lung to the thyroid. We reviewed similar reports through PubmMed search from 1997 until 201...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2017
ISSN: 0903-1936,1399-3003
DOI: 10.1183/13993003.01520-2016